Employees: 5,379
Size Jiangsu Kanion Pharmaceutical (600557.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $989M, the 2179th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.00 on 18 Nov 2026.
Performance Over six months the shares fell 8.7%, against -17.5% for the median peer and -20.0% for the China market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue grew 8.3% over the last twelve months (peer median +9.2%); the operating margin is 7.4% (peer median 12.5%).
Valuation It trades at 19.8× forward earnings against a peer median of 21.4× (8th cheapest of 16).
Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.5 points above its cost of capital (6.7% WACC).
Next results Next results expected around 5 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.37B | CN¥3.27B | CN¥3.86B | CN¥4.81B | CN¥4.28B |
| Revenue growth | — | -15% | -20% | +12% | — |
| Gross profit | CN¥2.58B | CN¥2.28B | CN¥2.72B | CN¥3.46B | CN¥2.99B |
| EBITDA | n/a | CN¥448M | CN¥497M | CN¥610M | CN¥592M |
| Net income | CN¥316M | CN¥304M | CN¥392M | CN¥464M | CN¥434M |
| Free cash flow | CN¥15.8M | CN¥99.1M | CN¥248M | CN¥676M | CN¥789M |
| Capital expenditure | CN¥603M | CN¥522M | CN¥477M | CN¥311M | CN¥211M |
| Total debt | CN¥33.1M | CN¥407M | CN¥548M | CN¥471M | CN¥11.9M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600557.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.5% | -7.6% | 6th highest of 21 |
| 6-month return | -8.7% | -17.5% | 8th highest of 21 |
| Distance from 52-week high | -27.8% | -33.9% | 8th highest of 21 |
| Revenue growth (TTM) | +8.3% | +9.2% | 10th highest of 19 |
| Operating margin | 7.4% | 12.5% | 6th lowest of 19 |
| Forward P/E | 19.8× | 21.4× | 8th cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | 2.3% | 5.6% | 4th least demanding of 14 |
| Growth delivered (Del g) | +1.8% | +7.7% | 5th lowest of 14 |
| Hurdle (Req g minus delivered) | +0.5 pp | -3.3 pp | 7th most demanding of 14 |
| ROIC minus cost of capital | +2.5 pp | -0.4 pp | 7th highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $989M | -9% | +8% | 7% | 19.8× | 2.3% | +1.8% |
| Aarti Pharmalabs AARTIPHARM.NS | India | $984M | +44% | +13% | 18% | n/a | n/a | n/a |
| InventisBio 688382.SS | China | $982M | -47% | -61% | -563% | n/a | 6.5% | -60.6% |
| Chongqing Taiji Industry (Group) 600129.SS | China | $982M | -20% | -4% | 2% | 69.8× | n/a | n/a |
| Seaport Therapeutics SPTX | United States | $980M | +16% | n/a | n/a | n/a | n/a | n/a |
| Procter & Gamble Health PGHL.NS | India | $979M | +3% | +13% | 31% | 24.5× | 5.6% | +9.3% |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1,000M | +17% | +24% | 6% | 59.3× | 12.7% | +19.4% |
| Aurisco Pharmaceutical 605116.SS | China | $1.00B | -23% | +3% | 25% | 13.6× | -2.0% | +18.7% |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.00B | -49% | +32% | 14% | n/a | n/a | n/a |
| Nxera Pharma 4565.T | Japan | $974M | +46% | +24% | 14% | 25.8× | 17.7% | +27.3% |
| SAWAI 4887.T | Japan | $1.01B | -18% | +2% | 9% | 12.0× | n/a | n/a |
| Renhe Pharmacy 000650.SZ | China | $1.01B | -12% | -7% | 14% | 16.9× | -10.7% | -7.0% |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.02B | +1% | +27% | 4% | 21.4× | 4.3% | +3.5% |
| BeBetter Med 688759.SS | China | $960M | -58% | n/a | n/a | n/a | n/a | n/a |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $959M | -21% | -27% | -19% | 21.4× | n/a | n/a |
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.02B | -23% | +103% | 24% | 9.9× | 7.5% | -4.5% |
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.03B | -33% | -2% | 13% | 24.6× | 4.4% | +7.7% |
| SSY 2005.HK | Hong Kong | $948M | +8% | -4% | 12% | 12.5× | 2.3% | -0.5% |
| Strides Pharma Science STAR.NS | India | $946M | -17% | +11% | 14% | 15.9× | 17.6% | +7.8% |
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -10% | +7% | 9% | 7.7× | -0.3% | +12.1% |
| Ningbo Menovo Pharmaceutical 603538.SS | China | $945M | -48% | +19% | 9% | 42.3× | 11.6% | +4.9% |